In this presentation from Lymphoma & Myeloma 2016, Dr. Adriana C. Rossi discusses whether second- and third-line agents should be used upfront in combination for myeloma patients.
Click to Earn CME Credit: http://bit.ly/2mFGsEq
© 2016 Imedex, LLC.
Advertisement